Showing 1-10 of 749 results for "".
Holding Court in Melanoma: Choosing the Optimal Frontline Treatment Approach for Stage IV BRAF-Wild Type Melanoma
https://practicaldermatology.com/programs/cme/holding-court-in-melanoma-choosing-the-optimal-frontline-treatment-approach-for-stage-iv-braf-wild-type-melanoma/15436/How can we make an informed decision on which target combined with a PD-1 inhibitor provides the most benefit in patients with metastatic melanoma?Preventing Disease Recurrence with Adjuvant Therapy in Stage IIB/IIC Melanoma
https://practicaldermatology.com/programs/cme/preventing-disease-recurrence-adjuvant-therapy-stage-iibiic-melanoma/15392/Are you as excited as our experts are about immunotherapy for the adjuvant treatment of stage IIB/IIC melanoma? Tune in to find out why you should be!Holding Court in Melanoma: Choosing the Optimal Adjuvant Treatment Approach for Stage III BRAF-Mutant Melanoma
https://practicaldermatology.com/programs/cme/holding-court-in-melanoma-choosing-the-optimal-adjuvant-treatment-approach-for-stage-iii-braf-mutant-melanoma/15435/How can we choose the best adjuvant treatment strategy for melanoma patients with BRAF-activating tumors? Don’t miss this series.Invasive Melanoma: Incidence, Mortality Continue to Climb
https://practicaldermatology.com/topics/practice-management/invasive-melanoma-incidence-mortality-continue-to-climb/20780/The burden of disease is growing, despite best efforts to combat melanoma.Pregnancy and Melanoma: What We Know About the Risks
https://practicaldermatology.com/topics/practice-management/pregnancy-and-melanoma-what-we-know-about-the-risks/21041/Against a backdrop of conflicting findings, a new study suggests a significant risk associated with melanoma during pregnancy.Panel Supports ATX-101; Melanoma Metastasis Test
https://practicaldermatology.com/topics/practice-management/dermwiretv-panel-supports-atx-101-melanoma-metastasis-test/18959/An FDA Advisory Panel Backs Kythera's ATX-101 for (Submental Fullness) or Double Chin, and a new genetic analysis may enhance SLN Biopsy findings to identify melanoma metastasis.Plus, Dan Siegel, MD, Darrell Rigel, MD, and Neal Bhatia, MD discuss the AAD's proposed dues increase and @NewDermMD launcTNF Inhibitors and the Risk of Melanoma
https://practicaldermatology.com/topics/skin-cancer-photoprotection/tnf-inhibitors-and-the-risk-of-melanoma/21519/New research offers a deeper look into the potential elevated risk for malignant melanoma from TNF treatment.Melanoma and the Predictive Value of Nevi: Unexpected Findings?
https://practicaldermatology.com/topics/practice-management/melanoma-and-the-predictive-value-of-nevi-unexpected-findings/20936/A new analysis shows that the association between nevi and melanoma is complex.Valeant Business Update; Melanoma Drugs Approved
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-valeant-business-update-melanoma-drugs-approved/18679/In this edition of DermWireTV from the editors of Practical Dermatology® magazine and DermWire.com, we take a look at Valeant's warning of disruption of dermatology business following its break from specialty pharmacy Philidor. Plus, an update on Melanoma Therapeutics, including approvals of ImlygicRegression in Primary Melanomas: Histologic Factors and Prognosis
https://practicaldermatology.com/topics/skin-cancer-photoprotection/regression-in-primary-melanomas-histologic-factors-and-prognosis/21367/Regression was once thought to be a negative prognostic factor in primary melanomas, but new findings suggest otherwise.
- Prev
- Next